FDA Inspection 1218140 — Advarra IRB
The FDA completed an inspection of Advarra IRB on Sep 15, 2023 in Columbia, MD. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Sep 15, 2023
- Fiscal Year
- 2023
- Product Type
- Biologics
- Project Area
- Bioresearch Monitoring
- Location
- Columbia, MD (United States)
Additional Details
IRB